JP2024522817A - フェニルピロールアミノグアニジン塩及び製剤 - Google Patents
フェニルピロールアミノグアニジン塩及び製剤 Download PDFInfo
- Publication number
- JP2024522817A JP2024522817A JP2023578136A JP2023578136A JP2024522817A JP 2024522817 A JP2024522817 A JP 2024522817A JP 2023578136 A JP2023578136 A JP 2023578136A JP 2023578136 A JP2023578136 A JP 2023578136A JP 2024522817 A JP2024522817 A JP 2024522817A
- Authority
- JP
- Japan
- Prior art keywords
- oral formulation
- pharma
- ceutically acceptable
- acceptable salt
- pyrrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21180708 | 2021-06-21 | ||
| EP21180708.6 | 2021-06-21 | ||
| EP21180702.9 | 2021-06-21 | ||
| EP21180702 | 2021-06-21 | ||
| EP21209855 | 2021-11-23 | ||
| EP21209855.2 | 2021-11-23 | ||
| PCT/EP2022/066906 WO2022268825A1 (en) | 2021-06-21 | 2022-06-21 | Phenyl pyrrole aminoguanidine salts and formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522817A true JP2024522817A (ja) | 2024-06-21 |
| JP2024522817A5 JP2024522817A5 (cg-RX-API-DMAC7.html) | 2025-06-30 |
Family
ID=84544160
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578136A Pending JP2024522817A (ja) | 2021-06-21 | 2022-06-21 | フェニルピロールアミノグアニジン塩及び製剤 |
| JP2023578832A Pending JP2024523459A (ja) | 2021-06-21 | 2022-06-21 | フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578832A Pending JP2024523459A (ja) | 2021-06-21 | 2022-06-21 | フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12661336B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4359383A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024522817A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240024818A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022296767A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023026909A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3220756A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3045575T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL309102A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2023014174A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2022268825A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024523459A (ja) * | 2021-06-21 | 2024-06-28 | シナクト ファーマ エーピーエス | フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3175172A1 (en) * | 2020-03-31 | 2021-10-07 | Synact Pharma Aps | Treatment of symptomatic viral diseases |
| EP4522160A1 (en) * | 2022-05-12 | 2025-03-19 | SynAct Pharma ApS | Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis |
| EP4637921A1 (en) * | 2022-12-21 | 2025-10-29 | SynAct Pharma ApS | Polymorph of phenyl pyrrole hydrazine carboximidamide compound |
| AU2024398488A1 (en) | 2023-12-11 | 2026-06-04 | Synact Pharma Aps | Treatment of subpopulation of patients with rheumatoid arthritis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020229297A1 (en) * | 2019-05-10 | 2020-11-19 | Synact Pharma Aps | Combination treatment of arthritic disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604348D0 (sv) | 1996-11-26 | 1996-11-26 | Wapharm Ab | Användning av hydroxyguanidiner |
| AU7464998A (en) | 1997-10-27 | 1999-05-17 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
| US6127381A (en) | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| HK1044954B (en) | 1999-03-29 | 2008-11-21 | The Procter & Gamble Company | Melanocortin receptor ligands |
| WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| AU6605800A (en) | 1999-07-16 | 2001-02-05 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| AU781880B2 (en) | 1999-09-17 | 2005-06-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
| WO2001055106A2 (en) | 2000-01-28 | 2001-08-02 | Melacure Therapeutics Ab | Novel melanocortin receptor agonists and antagonists |
| GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
| KR100440370B1 (ko) | 2000-04-01 | 2004-07-19 | (주)명문엘씨 | 2중 사출에 의한 밀폐용기 뚜껑 |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| US20030069169A1 (en) | 2001-03-02 | 2003-04-10 | Macor John E. | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
| GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| CA2363528A1 (en) | 2001-11-19 | 2003-05-19 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Immediate release tablet containing naproxen sodium |
| GB2398299A (en) | 2003-02-13 | 2004-08-18 | Melacure Therapeutics Ab | Pharmaceutically active phenyl-pyrrole derivatives |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| SI2348016T1 (sl) | 2006-06-09 | 2016-10-28 | Synact Pharma Aps | Derivati fenil pirol aminogvanidina |
| GB0624987D0 (en) | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| EP2045250A1 (en) | 2007-09-26 | 2009-04-08 | Action Pharma A/S | Ring-substituted phenyl pyrrole aminoguanidine derivatives |
| WO2009071101A1 (en) | 2007-12-07 | 2009-06-11 | Action Pharma A/S | N-modified aminoguanidine derivatives |
| WO2009074157A1 (en) | 2007-12-13 | 2009-06-18 | Action Pharma A/S | Fully-modified phenyl pyrrole aminoguanidines |
| US10387927B2 (en) | 2010-01-15 | 2019-08-20 | Dell Products L.P. | System and method for entitling digital assets |
| EA201290860A1 (ru) | 2010-03-03 | 2013-04-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата |
| JP2011190199A (ja) | 2010-03-12 | 2011-09-29 | Hideto Nakamura | 関節リウマチ薬 |
| US9662807B2 (en) | 2011-12-21 | 2017-05-30 | GKN Aerospace Services Structures, Corp. | Method for forming a fabric preform for a composite material by separately tensioning tows |
| WO2014060606A1 (en) | 2012-10-19 | 2014-04-24 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| US9917808B2 (en) | 2013-03-14 | 2018-03-13 | International Business Machines Corporation | Grouping electronic messages |
| WO2015162483A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| WO2015162486A1 (en) | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues |
| WO2017141343A1 (ja) | 2016-02-16 | 2017-08-24 | 三菱電機株式会社 | 圧縮機 |
| ES2899200T3 (es) | 2018-06-22 | 2022-03-10 | Synact Pharma Aps | Tratamiento de proteinuria |
| WO2020107221A1 (en) | 2018-11-27 | 2020-06-04 | Tsinghua University | Chemical activators of nicotinamide mononucleotide adenlyly transferase 2 (nmnat2) and uses thereof |
| CA3175172A1 (en) * | 2020-03-31 | 2021-10-07 | Synact Pharma Aps | Treatment of symptomatic viral diseases |
| CN113730797B (zh) | 2020-05-29 | 2023-05-16 | 创领心律管理医疗器械(上海)有限公司 | 电极板及可穿戴式除颤设备 |
| IL309102A (en) * | 2021-06-21 | 2024-02-01 | Synact Pharma Aps | Salts and formulations of phenyl pyrrole aminoguanidine |
-
2022
- 2022-06-21 IL IL309102A patent/IL309102A/en unknown
- 2022-06-21 JP JP2023578136A patent/JP2024522817A/ja active Pending
- 2022-06-21 WO PCT/EP2022/066906 patent/WO2022268825A1/en not_active Ceased
- 2022-06-21 CA CA3220756A patent/CA3220756A1/en active Pending
- 2022-06-21 KR KR1020237043107A patent/KR20240024818A/ko active Pending
- 2022-06-21 AU AU2022296767A patent/AU2022296767A1/en active Pending
- 2022-06-21 IL IL309104A patent/IL309104A/en unknown
- 2022-06-21 MX MX2023014174A patent/MX2023014174A/es unknown
- 2022-06-21 EP EP22735858.7A patent/EP4359383A1/en active Pending
- 2022-06-21 WO PCT/EP2022/066884 patent/WO2022268814A1/en not_active Ceased
- 2022-06-21 EP EP22737436.0A patent/EP4359076B1/en active Active
- 2022-06-21 AU AU2022300305A patent/AU2022300305A1/en active Pending
- 2022-06-21 CA CA3220753A patent/CA3220753A1/en active Pending
- 2022-06-21 KR KR1020247000873A patent/KR20240024177A/ko active Pending
- 2022-06-21 ES ES22737436T patent/ES3045575T3/es active Active
- 2022-06-21 JP JP2023578832A patent/JP2024523459A/ja active Pending
- 2022-06-21 EP EP25194012.8A patent/EP4684835A3/en active Pending
- 2022-06-21 BR BR112023026909A patent/BR112023026909A2/pt not_active Application Discontinuation
- 2022-06-21 MX MX2023014177A patent/MX2023014177A/es unknown
- 2022-08-23 US US17/821,500 patent/US12661336B2/en active Active
- 2022-12-14 US US18/065,702 patent/US20230114865A1/en active Pending
-
2024
- 2024-05-29 US US18/676,679 patent/US12239631B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020229297A1 (en) * | 2019-05-10 | 2020-11-19 | Synact Pharma Aps | Combination treatment of arthritic disease |
Non-Patent Citations (1)
| Title |
|---|
| J PHARMACEUTICAL SCIENCES, vol. 107:419-425, JPN6026021522, 2018, ISSN: 0005875217 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024523459A (ja) * | 2021-06-21 | 2024-06-28 | シナクト ファーマ エーピーエス | フェニルピロールアミノグアニジンの塩及びフェニルピロールアミノグアニジウム塩の多形体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4359076A1 (en) | 2024-05-01 |
| JP2024523459A (ja) | 2024-06-28 |
| AU2022296767A1 (en) | 2024-02-01 |
| AU2022300305A1 (en) | 2024-01-25 |
| EP4359076C0 (en) | 2025-08-06 |
| US20230114865A1 (en) | 2023-04-13 |
| KR20240024818A (ko) | 2024-02-26 |
| EP4359076B1 (en) | 2025-08-06 |
| IL309104A (en) | 2024-02-01 |
| US12239631B2 (en) | 2025-03-04 |
| EP4684835A2 (en) | 2026-01-28 |
| US20230271922A9 (en) | 2023-08-31 |
| WO2022268825A1 (en) | 2022-12-29 |
| ES3045575T3 (en) | 2025-11-28 |
| CA3220753A1 (en) | 2022-12-29 |
| MX2023014174A (es) | 2024-03-01 |
| US20230002319A1 (en) | 2023-01-05 |
| IL309102A (en) | 2024-02-01 |
| WO2022268814A1 (en) | 2022-12-29 |
| BR112023026909A2 (pt) | 2024-03-05 |
| MX2023014177A (es) | 2024-03-26 |
| KR20240024177A (ko) | 2024-02-23 |
| US12661336B2 (en) | 2026-06-23 |
| US20240335423A1 (en) | 2024-10-10 |
| EP4684835A3 (en) | 2026-04-08 |
| CA3220756A1 (en) | 2022-12-29 |
| EP4359383A1 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3045575T3 (en) | Phenyl pyrrole aminoguanidine salts and formulations | |
| JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
| US12102637B2 (en) | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis | |
| US20100209495A1 (en) | Granulates, process for preparing them and pharmaceutical products containing them | |
| JP2010511663A5 (cg-RX-API-DMAC7.html) | ||
| US20190054088A1 (en) | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis | |
| JP2009534462A (ja) | ニメスリドを含有する新規な低用量医薬組成物、その調製および使用 | |
| CN107205969B (zh) | 糖尿病治疗用药物组合物 | |
| CN101237858A (zh) | 胃滞留制剂及其制备方法 | |
| US20250170065A1 (en) | Therapeutic compounds, formulations, and use thereof | |
| CA3245018A1 (en) | THERAPEUTIC COMPOUNDS, FORMULATIONS AND THEIR USE | |
| JP2814513B2 (ja) | 溶出性の改良された製剤組成物 | |
| JPH0140009B2 (cg-RX-API-DMAC7.html) | ||
| BR122025026872A2 (pt) | Forma de dosagem sólida oral de liberação imediata e seu uso | |
| JP3122730B2 (ja) | ロキソプロフェン・ナトリウム含有錠剤製剤 | |
| JP7355846B2 (ja) | 固形製剤 | |
| HK40110368A (en) | Phenyl pyrrole aminoguanidine salts and formulations | |
| HK40110368B (en) | Phenyl pyrrole aminoguanidine salts and formulations | |
| JP2000264839A (ja) | 結腸領域で高まった疼痛感応性と関連する機能障害及び/又は下行腸管の疾患の治療及び/又は予防のための医薬調剤並びにその製造法 | |
| CN117642382A (zh) | 苯基吡咯氨基胍盐和制剂 | |
| RU2584653C2 (ru) | Фармацевтическая композиция с пролонгированным высвобождением с антипсихотической активностью и способы её получения | |
| WO2025162195A1 (zh) | 包衣复方片剂 | |
| TR2023018923A2 (tr) | Li̇nagli̇pti̇n ve metformi̇n i̇çeren farmasöti̇k tablet formülasyonlari | |
| EA052180B1 (ru) | Терапевтические соединения, составы и их применение | |
| JPWO2020246526A1 (ja) | キサンチンオキシダーゼ阻害剤含有腸溶性製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250620 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250620 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260602 |